April – JuneSignificant events during the quarter Positive top-line results from the MIV-711 osteoarthritis phase IIa extension study. The study met...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced positive top-line results from the MIV-711 phase IIa extension study (MIV-711-202)....
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Board of Directors have decided to continue the discussions...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that the design of the ongoing phase I/II study of birinapant...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that additional data from the phase II study of remetinostat in...
Read moreApproval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing directorThe...
Read moreStockholm, Sweden - Medivir AB (”Medivir” or the ”Company”) (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes...
Read moreSignificant events during the quarter The holders of series A shares have notified the Company that they will convert all their...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that data from the initial phase IIa study of MIV-711, which...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new preclinical data for MIV-818 will be presented during the...
Read moreStockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2017 now is available at the...
Read moreThe shareholders in Medivir AB are hereby summoned to the Annual General Meeting on Thursday 3 May 2018 at 2 p.m....
Read more